Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAH Regimen Followed by Allo-HSCT in Intermediate/High-Risk Newly Diagnosed AML
NCT06483906Phase 2Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax, azacitidine, homoharringtonine in acute myeloid leukemia (AML), sponsored by Shanghai General Hospital. Started Jul 2024; status: recruiting.
02
Drugs
venetoclaxazacitidinehomoharringtonine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06483906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06483906.